Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations

Sonia L. Betancourt Cuellar, Diana P. Palacio, Marcelo F. Benveniste, Brett W. Carter, Wayne L. Hofstetter, Edith M. Marom

Research output: Contribution to journalArticlepeer-review

Abstract

Squamous cell carcinoma and adenocarcinoma represent approximately 98% of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, squamous cell carcinoma continues to be the predominant histologic type. Integrated positron emission tomography or computed tomography with 2-[fluorine18] fluro-2-deoxy-D-glucose is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of response to neoadjuvant therapy and detection of recurrent disease in patients with esophageal carcinoma. As with any other imaging modality, 2-[fluorine18] fluro-2-deoxy-D-glucose-positron emission tomography or computed tomography has strengths and limitations that should be understood in order to maximize its utility.

Original languageEnglish (US)
Pages (from-to)571-583
Number of pages13
JournalSeminars in Ultrasound, CT and MRI
Volume38
Issue number6
DOIs
StatePublished - Dec 2017
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations'. Together they form a unique fingerprint.

Cite this